1. Home
  2. LEGN vs CADE Comparison

LEGN vs CADE Comparison

Compare LEGN & CADE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • CADE
  • Stock Information
  • Founded
  • LEGN 2014
  • CADE 1876
  • Country
  • LEGN United States
  • CADE United States
  • Employees
  • LEGN N/A
  • CADE N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • CADE Major Banks
  • Sector
  • LEGN Health Care
  • CADE Finance
  • Exchange
  • LEGN Nasdaq
  • CADE Nasdaq
  • Market Cap
  • LEGN 5.9B
  • CADE 7.0B
  • IPO Year
  • LEGN 2020
  • CADE N/A
  • Fundamental
  • Price
  • LEGN $29.60
  • CADE $37.66
  • Analyst Decision
  • LEGN Strong Buy
  • CADE Hold
  • Analyst Count
  • LEGN 13
  • CADE 11
  • Target Price
  • LEGN $72.92
  • CADE $41.00
  • AVG Volume (30 Days)
  • LEGN 1.3M
  • CADE 5.6M
  • Earning Date
  • LEGN 11-12-2025
  • CADE 10-20-2025
  • Dividend Yield
  • LEGN N/A
  • CADE 2.92%
  • EPS Growth
  • LEGN N/A
  • CADE N/A
  • EPS
  • LEGN N/A
  • CADE 2.77
  • Revenue
  • LEGN $909,045,000.00
  • CADE $1,794,761,000.00
  • Revenue This Year
  • LEGN $68.68
  • CADE $16.69
  • Revenue Next Year
  • LEGN $48.49
  • CADE $10.30
  • P/E Ratio
  • LEGN N/A
  • CADE $13.60
  • Revenue Growth
  • LEGN 74.75
  • CADE 41.19
  • 52 Week Low
  • LEGN $27.34
  • CADE $25.22
  • 52 Week High
  • LEGN $45.30
  • CADE $40.23
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 30.03
  • CADE 49.14
  • Support Level
  • LEGN $29.92
  • CADE $36.84
  • Resistance Level
  • LEGN $33.50
  • CADE $39.38
  • Average True Range (ATR)
  • LEGN 1.31
  • CADE 0.81
  • MACD
  • LEGN -0.21
  • CADE -0.01
  • Stochastic Oscillator
  • LEGN 7.78
  • CADE 31.10

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About CADE Cadence Bank

Cadence Bank is a bank based in the United States. The operating segments are Corporate Banking segment focuses on C&I, business banking, and commercial real estate lending to clients in the geographic footprint, Community Banking segment provides a broad range of banking services through the branch network to serve the needs of community businesses and individual consumers in the geographic footprint, Mortgage segment includes mortgage banking activities of originating mortgage loans, selling mortgage loans in the secondary market and servicing the mortgage loans, Banking Services segment offers individuals, businesses, governmental institutions, and non-profit entities a widerange of solutions to help protect, grow, and transfer wealth, General Corporate and Other segment.

Share on Social Networks: